Proteomics analysis of sera of asymptomatic, early-stage patients with Wilson’s disease

Jung-Young Park1*, Joo Hee Mun1*, Beom Hee Lee2, Sun Hee Heo1, Gu-Hwan Kim1 and Han-Wook Yoo1,2

1 Genome Research Center for Birth Defects and Genetic Diseases, Asan Institute for Life Sciences, Seoul, Korea
2 Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Wilson’s disease (WD) is characterized by excessive accumulation of intracellular copper in liver and extrahepatic tissues, leading to significant oxidative stress and tissue damage. To date, several diagnostic biomarkers for WD such as serum ceruloplasmin, serum or urine copper levels and copper content in liver have been identified. However, these biomarkers may not be convincing for the diagnosis in some WD patients. To identify additional novel diagnostic biomarkers, we compared the serum protein profiles of asymptomatic childhood WD patients \((n=20)\), without neurologic manifestation or liver cirrhosis, with normal controls \((n=13)\). Fourteen spots, five up-regulated and nine down-regulated \((>2\text{-fold})\), were differentially expressed in WD patients in comparison to normal control on 2-DE. Among them, three spots were down-regulated in both male and female WD. MS/MS analysis revealed that the three spots were complement component C3, complement factor B and alpha-2 macroglobulin. By comparative proteome analysis, complement component C3, complement factor B and alpha-2 macroglobulin, which are related to oxidative stress and inflammation, turned out to be good candidates for novel diagnostic biomarkers for early stages of WD.

Keywords:
2-DE / Wilson’s disease

1 Introduction

Copper, an essential trace element in living organisms, acts as a cofactor for several enzymes due to its biologically suitable redox potential. However, excess copper leads to random oxidation of biomolecules with subsequent toxic effects [1]. Wilson’s disease (WD) is an autosomal recessive inherited copper metabolism disorder caused by mutation of the \(\text{ATP7B} \) gene [2, 3]. The incidence of WD is estimated as one in 30,000 in most populations [4]. Alterations in the \(\text{ATP7B} \) protein cause impaired copper efflux from the liver into bile and decreased incorporation of copper into ceruloplasmin (CP), leading to its accumulation in the liver [5]. Manifestation of WD can be variable. It can be incidentally detected in asymptomatic patients with abnormal liver function alone, whereas symptomatic, early-stage patients can be found with chronic liver disease, liver cirrhosis or neurological impairment. The early diagnosis of WD is important because it can be lethal when left untreated. Patients with WD show decreased serum CP, increased urinary excretion of copper, elevated hepatic copper concentration and Kayser–Fleischer rings on cornea [6, 7]. Although serum CP, serum/urine copper levels and copper

*These authors contributed equally to this work.
content in liver tissue are considered as diagnostic biomarkers of WD, 5–40% of the patients with WD display normal CP levels, and serum/urine copper levels may be equivocal [8, 9]. In addition, invasive study is often required to evaluate copper content in liver. Therefore, diagnosis can be indeterminate, especially in asymptomatic, early-stage patients.

This study was undertaken to find novel biomarkers of asymptomatic, early-stage WD. Using comparative proteome analyses, including multiple affinity removal columns (MARC), 2-DE and MALDI-TOF, we identified the differently expressed proteins and we discussed their functional roles in asymptomatic WD patients.

2 Materials and methods

2.1 Serum sample preparation

Serum samples were collected from 20 asymptomatic childhood WD patients, 12 males and 8 females, without neurologic manifestation or liver cirrhosis. All of them were detected by abnormal serum liver enzyme levels, which were incidentally found during health screening or preoperative examinations for minor surgical procedures not related to WD, such as tonsillectomy. WD was diagnosed based on low serum CP levels (<15 mg/dL) and increased urinary copper excretion (>100 μg/day). Thirteen age- and sex-matched individuals, six males and seven females, with normal liver functions and CP levels were classified as normal group. WD patients with same gender were randomly divided into two groups, male WD patients (mWD1/2) and female WD patients (fWD1/2), to give each group the same number of patients (Table 1). Samples from normal group and mWD1/2 and fWD1/2 were split into 300 μL aliquots, frozen and stored at −80°C. The total protein content was determined using the Bradford method, according to the manufacturer’s instructions (Bio-Rad Laboratories, Hercules, CA, USA). Written informed consent was obtained from each individual, and the research protocol approved by the Institutional Review Board (IRB) of Asan Medical Center, University of Ulsan College of Medicine (Seoul, Korea).

2.2 Depletion of major abundant proteins using MARC

Serum depletion was performed as described previously [10]. The six most abundant proteins in each serum sample were depleted using 4.6 × 100 mm MARC (Agilent, Wilmington, DE, USA) with a binding capacity of 20 μL of human serum. Chromatographic separation was performed using a mobile phase reagent kit, according to the standard LC protocol provided by the manufacturer. Serum samples were diluted fivefold with buffer A containing protease inhibitors (COMPLETE™, Roche), and filtered through 0.22 μm spin filters at 12 000 rpm for 1 min at room temperature. Flow-through MARC fractions were pooled and precipitated with a precooled solution of 10% trichloroacetic acid for 1 h at −20°C. Each precipitate was washed with ice-cold acetone, and redissolved in sample lysis buffer (7 M urea, 2 M thiourea, 100 mM DTT, 4.5% CHAPS and 40 mM Tris).

2.3 2-DE

MARC-treated samples (800 μg) were mixed with rehydration buffer (8 M urea, 2% CHAPS, 65 mM DTT, 0.5% IPG buffer), according to the manufacturer’s instructions, to a final volume of 340 μL, and applied onto immobilized pH 3–10NL strips (Amersham Biosciences, Uppsala, Sweden). Isoelectric focusing was performed at 80 000 Vh. Strips were applied to 12.5% polyacrylamide gels and electrophoresed until the dye reached end of the gel. After protein fixation for 1 h, gels were stained with Coomassie Brilliant Blue G250 for 24 h, destained with H2O, scanned in a Umax power Look 1100 (Umax data system) and converted into electronic files, which were analyzed with the Image Master Platinum 5.0 image analysis program (Amersham Biosciences). Spot detection parameters were adjusted using a smooth by Algorithm. The number of spots was automatically determined and matched. The normalized volume was quantified as percentage volume (%v), where %v = spot volume/percentage volume (%v), where %v = spot volume/number of spots.

Table 1. Clinical data on control subjects and WD patients

| Sex      | Group      | Number | Age mean (range) | CP (mg/dL) mean (± SD) | Copper serum (ug/dL) mean (± SD) | AST(IU/L) mean (± SD) | ALT(IU/L) mean (± SD) |
|----------|------------|--------|------------------|------------------------|---------------------------------|----------------------|----------------------|
| Male     | Normal     | 6      | 9 (5–12)         | 33 (± 6.5)             | 115 (± 17.5)                    | 35 (± 10)            | 25 (± 10)            |
|          | mWD1(a)    | 6      | 9 (5–12)         | 2.2 (± 0.7)            | 13.4 (± 7.9)                    | 279 (± 228)          | 361 (± 241)          |
|          | mWD2       | 6      | 9 (6–12)         | 4.1 (± 2.0)            | 18.8 (± 9.9)                    | 221 (± 193)          | 260 (± 224)          |
| Female   | Normal     | 7      | 7 (5–12)         | 32 (± 5)               | 105 (± 17.5)                    | 27.5 (± 6.3)         | 17.5 (± 8.8)         |
|          | fWD1(b)    | 4      | 8 (5–12)         | 3.2 (± 0.7)            | 22.6 (± 17.6)                   | 143 (± 84)           | 242 (± 187)          |
|          | fWD2       | 4      | 8 (6–10)        | 2.7 (± 0.4)            | 18.4 (± 8.6)                    | 134 (± 67)           | 218 (± 102)          |

a) Aspartate aminotransferase: GOT.
b) Alanine aminotransferase: GPT.
c) Male Wilson’s disease group.
d) Female Wilson’s disease group.
2.4 Identification of proteins using MS/MS

Protein spots were excised from CBB-stained gels, and digested with trypsin (Promega, Madison, WI, USA). Tryptic peptides were concentrated on POROS R2 and oligo R3 columns (Applied Biosystems, Foster City, CA, USA). After washing each column with 70 and 100% ACN and 50 mM ammonium bicarbonate, samples were applied to the R2 and R3 columns, and eluted with CHCA (Sigma, St. Louis, MO) dissolved in 70% ACN and 0.1% TFA before MALDI-TOF analysis [11]. Mass spectra were acquired on a 4700 Proteomics Analyzer (Applied Biosystems) operated in the MS and MS/MS modes. The mass spectrometer was set to acquire positive ion MS survey scans over the mass range of 700–4000 Da. The data were processed to generate a list of precursor ions for interrogation by MS/MS. Each raw spectrum was opened in Data Explorer software and less than 40 top mass peaks were selected by S/N threshold setting and then treated with advanced base-line correction. The spectrum was calibrated with more than two peptides resulting from trypsin autolysis \((m/z\ 842.5100, 2211.1046)\). Peak list of monoisotopic masses was searched using the following parameters: trypsin as enzyme, one possible missed cleavage, peptide tolerance of 0.5 Da and mass tolerance of 100 ppm. Peptide mass fingerprinting was performed using the MASCOT search engine (http://matrixscience.com/) included in GPS Explorer software and ProFound program (http://prowl.rockefeller.edu/). Mass spectra were used for manual de novo sequencing, and sequences annotated with Data Explorer software (Applied Biosystems). Peptide matching and protein searches were performed using SwissProt and NCBI databases (ver.20061110, 4111659 sequences; 1417848065).

2.5 Western blot analysis

Serum proteins (30 µg) were subjected to electrophoresis on 10% SDS-polyacrylamide gels, and transferred to PVDF membranes (Bio-Rad). After overnight blocking with blocking buffer (TBS, 5% skimmed milk, 0.1% Tween 20), membranes were incubated with polyclonal antibodies against alpha-2 macroglobulin (α2M), complement component C3 (C3), and complement factor B (FB) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by HRP-labeled secondary antibody. Blots were visualized using the SuperSignal West Pico Chemiluminescent Substrate (PIERCE, UK) detection system, according to the manufacturer’s instructions. An antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was employed as the internal control.

2.6 Statistical analysis

All statistical analyses were performed using SPSS 12.0 software. Student’s t-test was applied to compare differences between control subjects and WD patients.

![Figure 1. Partial 2-DE comparison images of normal subjects and asymptomatic WD patients. Differentially expressed proteins displaying >2-fold difference in levels are indicated with numbered arrows.](http://www.clinical.proteomics-journal.com)
Table 2. Differentially expressed proteins in sera of normal subjects and asymptomatic WD patients, identified using MALDI-TOF MS and MS/MS

| Spot no. | Protein name                  | Accession no. | MALDI-TOF MS | MS/MS b) | Matched peptides (%) | Score Decision DB (MASCOT c)/ peptides (%) | Matched peptides (%) | Score Decision DB (MASCOT c)/ peptides (%) |
|---------|-------------------------------|---------------|--------------|---------|----------------------|---------------------------------------------|----------------------|---------------------------------------------|
| 1       | Complement factor B, preproprotein | Q53F89 | 5.5          | 3.1     | gi|4502397 | 103 MASCOT 11/25 (44%) 242 4/43 (9%) |
| 2       | Alpha-2-macroglobulin precursor | P01023 | 2.7          | gi|112911 | 153 MASCOT 17/25 (68%) 469 4/53 (8%) |
| 3       | Complement factor B preproprotein | Q53F89 | 2.4          | gi|14124934 | 82 MASCOT 25/210 (12%) 141 |
| 4       | Hemoglobin Gower 2 epsilon     | P02100 | 3.4          | gi|223114 | 71 MASCOT 6/40 (15%) |
| 5       | Nesprin-1 beta 2               | Q8NF91 | 4.4          | gi|370178 | 65 MASCOT 42/135 (31%) |
| 6       | Immunoglobulin heavy chain variable region | P01764 | 3.0          | gi|18307244 | 34 MASCOT 5/128 (4%) |
| 7       | Ig heavy chain V region (clone P1–53) | P23083 | 3.3          | gi|484705 | 66 MASCOT 5/25 (20%) |
| 8       | Isocitrate dehydrogenase 3 (NAD1/2M, alpha) | P50213 | 2.1          | gi|5031777 | 15 MASCOT 1/49 (2%) |
| 9       | Immunoglobulin heavy chain variable region | P01764 | 2.5          | gi|112701283 | 60 MASCOT 5/42 (12%) |
| 10      | Thiol-specific antioxidant protein (PRX2) | P32119 | 4.4          | gi|438069 | 87 MASCOT 17/115 (15%) 302 5/72 (7%) |
| 11      | Smad ubiquitination regulatory factor 1 | P05787 | 6.9          | gi|10047327 | 24 MASCOT 1/44 (2%) |
| 12      | Haptoglobin precursor          | P00738 | 3.8          | gi|67586 | 24 MASCOT 1/25 (4%) |

b) Individual ions scores > 3 indicate identity or extensive homology (p < 0.05). Ions score is –10 log (p), where p is the probability that the observed match is a random event.

c) Expectation value scoring was used, which indicates the quality or significance of the match.

d) Immunoglobulin heavy chain variable region | P01764 | 2.0          | gi|30313 | 63 MASCOT 1/47 (2%) |

3 Results

Serum protein profiles of mWD1/2, fWD1/2 and normal individuals were analyzed using 2-DE, visualized by staining with Coomassie Brilliant Blue G-250, and compared using the Image Master Platinum 5.0 program (data not shown). Comparing serum protein profiles between mWD1/2 and fWD1/2 and normal control, five spots were up-regulated (spots 4–7 and 9) and nine down-regulated (spots 1–3, 8, and 10–14) by at least twofold in depleted sera of asymptomatic WD regard less of sex (Fig. 1). The selected spots were re-analyzed using MALDI-TOF MS and subsequently confirmed by MS/MS (Table 2). Finally, spots 1, 2, 3, 8 and 11 were confirmed to be down-regulated in both male and female WD patients (Fig. 1 and Table 2). Spots 1 and 3, spot 2 and spot 11 were FB, C3 and z2M precursors, respectively. Western blot analysis for C3, FB and z2M also showed decreased expressions in WD patients (Fig. 2 and Supporting Information Fig. S1). Following normalization in relation to GAPDH expression, C3, FB and z2M levels were still decreased significantly in the sera of WD patients in comparison with those of normal subjects (Fig. 2). z2M expression was decreased to 2.3-fold in male and 1.8-fold in female WD patients (p < 0.001), C3 to 1.8-fold in male and 1.9 in female (p < 0.005) and FB to 2.4-fold in male and 1.6-fold in female (p < 0.005).

4 Discussion

In this study, three proteins, C3, FB and z2MG, were differentially expressed in asymptomatic WD patients. These proteins are known to be related with several functions including inflammation, regulation of the cell cycle and protection of cells against oxidative stress. C3 plays a central role in activation of the classical and alternative complement activation pathways [12], while FB is a crucial component that regulates alternative complement pathway [13, 14]. These proteins are synthesized primarily in the liver, which is induced during acute inflammatory processes. Down-regulations of C3 and FB in WD imply reduced activity of complement activation pathway in WD patients, which may be caused by excessive consumption and/or decreased synthesis due to hepatic copper toxicity.

z2M, a universal protease inhibitor and cytokine transporter, is an evolutionarily conserved component of the innate immune system [15, 16]. Moreover, z2M is a large molecular-sized plasma protein produced by hepatocytes [17] that is responsible for the inhibition and clearance of proteases secreted by endogenous and exogenous pathogens from the circulation [16]. Severe hepatocellular damage and chronic liver disease lead to reduced production of the z2M protein [18]. However, the WD patients enrolled in this study did not have a severe hepatic damage but elevated serum liver enzyme levels, which might lead to reduced production. Therefore, reduced expression of z2M in asymptomatic WD patients may indicate blunted acute
phase response to early stage of hepatitis induced by copper toxicity.

Besides three proteins, which were down-regulated, several proteins were differentially expressed in WD patients to a lesser degree (Table 2). Nesprin, which was up-regulated only in female WD, plays several fundamental roles including maintenance of structural organization, regulation of the cell cycle and maintaining/targeting protein complexes common to the nuclear envelope and sarcoplasmic reticulum, particularly in differentiated muscle cells [19]. Elevation of nesprin-1 beta2 may reflect damage to the cell membrane and cytoskeleton resulting from intracellular copper accumulation. Peroxiredoxin 2 isoform b with down-regulation in male WD is an intracellular antioxidant protein that protects cells from oxidative stress through redox regulation [20]. A reduction in the amount of peroxiredoxin 2 isoform b may therefore suggest increased cell susceptibility to oxidative damage induced by intracellular copper accumulation [21]. Smad proteins mediate signaling by members of the transforming growth factor-beta superfamily [22]. Smurf1 is a member of the Hect domain family of E3 ubiquitin ligases, which interacts with the bone morphogenic protein (BMP) signaling proteins, Smad1 and 5, the bone-specific transcription factor, Runx2/Cbfa1, and type I BMP receptors mediating their degradation [23]. Additionally, Smurf1 possibly plays an important role in osteoblast differentiation [24]. The relationship between decreased expression of Smurf1 in female WD and the pathogenetic effect on WD remains elusive, which is needed to be investigated. Haptoglobin, a liver glycoprotein, is primarily secreted by liver cells in response to a variety of stimuli [25]. This hemoglobin-binding serum protein participates in protection against heme-driven oxidative stress [26]. Low haptoglobin levels are reported in various clinical conditions, including tumor metastasis, severe sepsis, hemolytic anemia and chronic liver disease [27, 28]. Moreover, haptoglobin has been reported as a potential serum biomarker of ovarian cancers [29, 30]. In our analysis, haptoglobin precursor was down-regulated in female WD (Table 2). In order to verify this result, we performed Western blot analysis with the whole sera of WD patients including male and female. The proportion of haptoglobin was decreased in both male and female WD compared with normal. However, haptoglobin of female WD showed a little more down-regulated pattern than male WD (Supporting Information Fig. S2). Profound depletion of haptoglobin precursor may imply the presence of asymptomatic hemolysis caused by copper toxicity to red blood cells as well as reduced synthesis from the damaged liver, but the reason for gender difference is yet to be known.

In conclusion, our experiments indicate that C3, FB and α2M are down-regulated in asymptomatic WD patients implying impaired cellular response to inflammatory stimulus, which might be caused by intracellular copper accumulation in hepatic tissue. These proteins can be candidates for novel diagnostic biomarkers for WD, particularly in the asymptomatic stage.

This study was supported by a grant from the Korea Health 21 R&D Project (Ministry of Health, Welfare and Family Affairs, Republic of Korea, A010384 and A030003).

The authors have declared no conflict of interest.

5 References

[1] Bissig, K. D., Honer, M., Zimmermann, K., Summer, K. H. et al. Whole animal copper flux assessed by positron emission tomography in the Long-Evans cinnamon rat – a feasibility study. Biometals 2005, 18, 83–88.

[2] Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. R. et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 1993, 5, 327–337.

[3] Tanzi, R. E., Petrukhin, K. E., Chernov, I., Pellequer, J. L. et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet. 1993, 5, 344–350.
Vrabelova, S., Letocha, O., Borsky, M., Kozak, L., Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol. Genet. Metab. 2005, 86, 277–285.

Klein, D., Lichtmannegger, J., Finckh, M., Summer, K. H. Gene expression in the liver of Long-Evans cinnamon rats during the development of hepatitis. Arch. Toxicol. 2003, 77, 568–575.

Yucu, A., Kocuk, N., Ozen, H., Gurak, F. Wilson’s disease patients with normal ceruloplasmin levels. Turk. J. Pediatr. 1999, 41, 99–102.

Park, S., Park, J. Y., Kim, G. H., Choi, J. H. et al. Identification of novel ATP7B gene mutations and their functional roles in Korean patients with Wilson disease. Hum. Mutat. 2007, 28, 1108–1113.

Steindl, P., Ferenci, P., Dienes, H. P., Grimm, G. et al. mutation in the ATP7B gene in a large, inbred Hungarian kindred with Wilson disease. Hum. Mutat. 1997, 113, 212–218.

Sternlieb, I. Diagnosis of Wilson’s disease. Gastroenterology 1997, 74, 787–789.

Cho, S. Y., Lee, E. Y., Lee, J. S., Kim, H. Y. et al. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics 2005, 5, 3386–3396.

Choi, B. K., Cho, Y. M., Bae, S. H., Zouboulis, C. C. et al. Single-step perfusion chromatography with a throughput potential for enhanced peptide detection by matrix-assisted laser desorption/ionization-mass spectrometry. Proteomics 2003, 3, 1955–1961.

de Bruijn, M. H., Fey, G. H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. USA 1985, 82, 708–712.

Spencer, K. L., Hauser, M. A., Olson, L. M., Schmidt, S. et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum. Mol. Genet. 2007, 16, 1986-1992.

Le, G. T., Abbenante, G., Fairlie, D. P. Profiling the enzymatic properties and inhibition of human complement factor B. J. Biol. Chem. 2007, 282, 24809–24816.

Padhi, A., Buchheim, M. A., Verghese, B. Dynamic evolutionary pattern of alpha2-macroglobulin in a model organism, the zebrafish. Mol. Immunol. 2008, 45, 3312–3318.

Armstrong, P. B., Quigley, J. P. α2-macroglobulin: an evolutionarily conserved arm of the innate immune system. Dev. Comp. Immunol. 1999, 23, 375–390.

Andus, T., Gross, V., Tran-Thi, T. A., Schreiber, G. et al. The biosynthesis of acute-phase proteins in primary cultures of rat hepatocytes. Eur. J. Biochem. 1983, 133, 561–571.

Nielsen, S. S., Grofte, T., Tygstrup, N., Viilstrup, H. Synthesis of acute phase proteins in rats with cirrhosis exposed to lipopolysaccharide. Comp. Hepatol. 2006, 5, 3.

Warren, D. T., Zhang, O., Weissberg, P. L., Shanahan, C. M. Nesprins: intracellular scaffolds that maintain cell architecture and coordinate cell function? Expert. Rev. Mol. Med. 2005, 7, 1–15.

Hofmann, B., Hecht, H. J., Flohe, L., Peroxiredoxins. Biol. Chem. 2002, 383, 347–364.

Yamamoto, T., Kikkawa, R., Yamada, H., Horii, I. Identification of oxidative stress-related proteins for predictive screening of hepatotoxicity using a proteomic approach. J. Toxicol. Sci. 2005, 30, 213–227.

Heldin, C. H., Miyazono, K., ten Dijke, P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390, 465–471.

Murakami, G., Watabe, T., Takaoka, K., Miyazono, K. et al. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. Cell 2003, 14, 2809–2817.

Ying, S. X., Hussain, Z. J., Zhang, Y. E. Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic protein-2-induced osteoblast conversion by targeting Smad5 for degradation. J. Biol. Chem. 2003, 278, 39029–39036.

Bowman, B. H., Kurosky, A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv. Hum. Genet. 1982, 12, 189–261.

Langlois, M. R., Delanghe, J. R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 1996, 42, 1589–1600.

Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P. et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 2003, 9, 2904–2911.

Ahmed, N., Barker, G., Oliwa, K. T., Hoffmann, P. et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br. J. Cancer 2004, 91, 129–140.

Fischbach, F. T., A Manual of Laboratory Diagnostic Tests, Lippincott, Philadelphia 1996, pp. 95–97.

Mcclatchey, K. D., Clinical Laboratory Medicine, Williams & Wilkins, Baltimore 1994, pp. 239–257.